Patient-Reported functional outcomes after hypofractionated or conventionally fractionated radiation for prostate cancer: A national cohort study in england
Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received
Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up
The Phoenix criteria for biochemically recurrent prostate cancer after curative radiotherapy appear obsolete in the era of prostate-specific membrane antigen PET: A plea for urgent re-evaluation of current guidelines
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial